Clinical Trial Update: Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update on Alirocumab testing safety, tolerability, and bioeffects in non-treatment seeking heavy drinkers; study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alcohol-associated Liver Disease

Drugs mentioned

• alirocumab (alirocumab)

Snippet

Sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Conditions: Alcohol Associated Liver Disease, Heavy Drinking Behavior | Phase 1 | Status: RECRUITING